ZAPI GROUP Showcases Advanced Solutions to Electrify the Agricultural Sector
2.11.2023 16:00:00 EET | Business Wire | Press release
ZAPI GROUP, a global leader in electrification, is proud to announce its participation in AGRITECHNICA 2023, the world's leading trade fair for agricultural machinery, taking place from November 12 - 18, 2023, in Hanover, Germany.
ZAPI GROUP’s expertise in electric drivetrain systems - encompassing motion controllers, inverters, electric motors, battery chargers, and autonomous navigation software - presents an ideal partnership opportunity for OEMs seeking sustainable solutions on their path to electrification.
“We look forward to exhibiting at AGRITECHNICA and showcasing our electrification solutions for the agricultural sector,” said Claes Avasjö, Executive Director of ZAPI GROUP. “As the agricultural industry navigates the challenges of climate change, rising demands, and geopolitical forces, electrification of equipment is critical for a sustainable future. We look forward to discussing with attendees how to leverage technology to increase operational efficiencies, productivity and environmental sustainability.”
ZAPI GROUP's strategic portfolio of product brands offers a unique wealth of electrification expertise and solutions to agriculture companies planning to electrify their product ranges. Evidence of this can be seen through long-standing relationships with high-volume tier-one OEMs in the off-highway markets. ZAPI GROUP's team of product companies, including Zapi SpA, Schabmuller, Delta-Q, ZIVAN, Inmotion, BlueBotics, BestMotor and Schabmüller, will be at the event to showcase their electric drivetrain solutions to the agricultural machinery sector.
One highlight of ZAPI GROUP's presence at AGRITECHNICA 2023 will be a shared presentation by Delta-Q and Inventus Power titled “Off-Highway Vehicle Electrification: Best Practices in Battery & Charger Integration.” This session will take place on November 16 from 10:30 a.m. - 11 a.m. on the Expert Stage within the Systems and Components section of the fair.
ZAPI GROUP invites all attendees to visit its booth located in Hall 15, Stand H11. Visitors will have the opportunity to explore the latest products, consult experts, and discover how ZAPI GROUP can drive innovation and sustainability in the agricultural machinery industry. The company will also host its third annual Future of Electrification virtual conference from February 7-8, 2024.
About ZAPI GROUP
ZAPI GROUP is engineering the transition to an all-electric future with a highly integrated product portfolio, including motion controllers, electric motors, high-frequency battery chargers and autonomous navigation software for application in full electric and hybrid vehicles. As a global electrification leader with deep systems experience, leading innovations and an obsession with driving customers' success, ZAPI GROUP now counts more than 1,500 employees worldwide with total annual revenue of more than 600 million US dollars. For more information, visit www.zapigroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231102772934/en/
Contact information
AnnMarie Carson, Communiqué PR
Phone: (206) 282-4923
ZapiGroupPR@communiquepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom